Suggested remit: To appraise the clinical and cost effectiveness of olaparib within its marketing authorisation for treating hormone-relapsed metastatic prostate cancer after treatment with hormonal therapy such as abiraterone or enzalutamide.
Status In progress
Process STA 2018
ID number 1640

Provisional Schedule

Committee meeting: 1 12 November 2020

Project Team

Project lead Jeremy Powell

Email enquiries


Companies sponsors AstraZeneca (olaparib)
Others Department of Health and Social Care
  NHS Darlington CCG
  NHS Wyre Forest CCG
  NHS England
  Welsh Government
Patient carer groups Black Health Agency
  Bob Champion Cancer Trust
  Cancer Black Care
  Cancer Equality
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  PCaSO - Prostate Cancer Support Organisation
  Pelican Cancer Foundation
  Prostate Cancer UK
  Prostate Help Association
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tackle Prostate Cancer
  Tenovus Cancer Care
Professional groups Association of Anaesthetists
  Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association of Urological Nurses
  British Association of Urological Surgeons
  British Geriatrics Society
  British Institute of Radiology
  British Prostate Group
  British Psychosocial Oncology Society
  British Uro-Oncology Group
  Cancer Research UK
  Prostate Cancer Advisory group
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society
  Urology Foundation


Comparator companies Accord (docetaxel)
  Bayer (radium-223 dichloride)
  Hospira (docetaxel)
  Sanofi (cabazitaxel)
  Seacross (docetaxel)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Urology
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
  Ovarian & Prostate Cancer Research Trust
  Pro Cancer Research Fund
  Prostate Cancer Research Centre


Key events during the development of the guidance:

Date Update
23 March 2020 Invitation to participate
10 January 2020 - 31 January 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 December 2019 In progress, Referred December 5 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance